EP3469089A1 - Composition de lysat d'euglena et procédé de production de la composition d et d'un bêta-1,3-glycane purifié - Google Patents

Composition de lysat d'euglena et procédé de production de la composition d et d'un bêta-1,3-glycane purifié

Info

Publication number
EP3469089A1
EP3469089A1 EP17810911.2A EP17810911A EP3469089A1 EP 3469089 A1 EP3469089 A1 EP 3469089A1 EP 17810911 A EP17810911 A EP 17810911A EP 3469089 A1 EP3469089 A1 EP 3469089A1
Authority
EP
European Patent Office
Prior art keywords
biomass
beta
glucan
lysing
drying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17810911.2A
Other languages
German (de)
English (en)
Other versions
EP3469089A4 (fr
Inventor
Brad Cox
Derek JAMROG
Kip ZURCHER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F3 Platform Biologics Inc
Original Assignee
F3 Platform Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/177,376 external-priority patent/US20170354698A1/en
Priority claimed from US15/177,368 external-priority patent/US20170356020A1/en
Priority claimed from US15/177,383 external-priority patent/US9901606B2/en
Application filed by F3 Platform Biologics Inc filed Critical F3 Platform Biologics Inc
Publication of EP3469089A1 publication Critical patent/EP3469089A1/fr
Publication of EP3469089A4 publication Critical patent/EP3469089A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/202—Algae extracts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/50—Polysaccharides, gums
    • A23V2250/502—Gums
    • A23V2250/5034—Beta-Glucan

Definitions

  • the present invention relates to the field of genus Euglena organisms, and more particularly, this invention relates to a Euglena lysate composition and method for producing the Euglena lysate and producing a purified beta-1,3-glucan.
  • Beta-glucans are a group of ⁇ -D-glucose polysaccharides that are produced by bacteria, yeast, algae, fungi, and in cereals.
  • the properties of the beta-glucans depend on the source, for example, whether from bacteria, algae, yeast or other sources.
  • beta-glucans form a linear backbone with 1 ,3 beta-glycosidic bonds. It is known that incorporating beta- glucans within a human or animal diet has advantages. Some beta-glucans may aid in immune modulation and decrease the levels of saturated fats and reduce the risk of heart disease. It is also known that different types of beta-glucans have different effects on human physiology. For example, cereal beta-glucans may affect blood glucose regulation in those having
  • yeast beta-glucans may decrease levels of IL4 and IL5 cytokines that relate to allergic rhinitis and increase the levels of IL12.
  • Euglena gracilis biomass containing paramyion (beta-l,3-glucan) can enhance the immune function of an individual.
  • Paramyion is a linear (unbranched) beta-l,3-glucan polysaccharide polymer with a high molecular weight This unbranched polymer is distinct from the other beta-glucans such as the branched
  • beta-glucan from Euglena lacks beta-( 1 ,6), beta(l ,4), and beta(l,2) bonds and any side branching structures.
  • this linear beta-glucan is insoluble and believed to be homogenous and have higher combined localization and binding affinities for receptors involved in immune response ' Paramyion may be obtained from Euglena gracilis algae, which is a protist organism, and a member of the micro-algae division euglenophyceae within the euglenales family and includes many different autotrophic and heterotrophic species which can also produce paramyion.
  • Paramyion is an energy-storage compound for the Euglenoids and comparable to the starch or oil and fats in other algae. Paramyion is produced in the pyrenoids and stored as granules in the cytoplasm. The paramyion granules in Euglena gracilis are oblong and about 0.5-2 micrometers (urn) in diameter. Euglena gracilis stock cultures are usually maintained in controlled laboratory conditions and used as an initial inoculum source. Euglena gracilis may be manufactured axenically in closed, sterilizable bioreactors. The Euglena gracilis inoculum may be transferred to seed bioreactors to accumulate larger amounts of biomass and then passaged up to larger bioreactors as needed.
  • a composition comprises a Euglena lysate and cellular components and residual media remaining from a fermentation process that produced a Euglena biomass and the Euglena lysate.
  • the composition may comprise a metal, including zinc and be formulated into a single dosage capsule or to be added as a nutritional supplement
  • the residual media may comprise at least one of minerals and vitamins.
  • the minerals and vitamins are selected from the group consisting of biotin, calcium, copper, folic acid, iron, magnesium, manganese, niacin, phosphorus, potassium, sodium, zinc and vitamins Bl, B2, B6, Bl 2, C, D,E, 1 or salts therefrom.
  • the cellular components may comprise lipids, proteins and amino acids.
  • the amino acids are selected from the group consisting of alanine, arginine, aspartic acid, cysteine, cystine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine.
  • the lipids are selected from the group consisting of arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, fats, linoleic acid, linolenic acid, oleic acid, palmitoleic acid, and pantothenic acid.
  • the composition may further comprise carotenoids, including alpha- and beta-carotene, astaxanthin, lutein, and zeaxanthin.
  • the composition may comprise a Euglena lysate and cellular components and residual media remaining from a fermentation process that produced a Euglena biomass and the Euglena lysate.
  • the cellular components may comprise one or more beta-glucan polymer chains having a molecular weight of 1.2 to 580 kilodaltons (kDa).
  • the beta-glucan polymer chains may have a polymer length of 7 to 3,400 glucose units.
  • a method for producing a Euglena lysate comprises growing a biomass from genus Euglena organisms, and in a non-limiting example, dewatering the grown biomass. The method further comprises lysing the biomass and drying the lysed biomass to form a Euglena lysate. A metal may be added to the Euglena lysate.
  • the dewatering may comprise centrif ging or gravity decanting the biomass.
  • the centrifuging may be selected from the group consisting of decanter, stacked-disk, conical plate, pusher, and peeler centrifuging.
  • the lysing may be selected from the group consisting of mechanical, pH and temperature driven.
  • the mechanical lysing may comprise homogenizing or bead milling.
  • the biomass may be homogenized at a pressure greater than 500 barg, and in another example, at a pressure range of 500 to 1,900 barg, and in yet another example, at a pressure range of 750 to 1,000 barg.
  • the biomass may be lysed at a pH greater than 7.0 and at a temperature greater than 5 degrees centigrade, and in another example, the biomass is treated with a base and lysed at a pH greater than 9.0 and at a temperature greater than 45 degrees centigrade.
  • the biomass may also be treated with a base and lysed at a pH between 9.0 to 12.5 and at a temperature between 45 to 100 degrees centigrade.
  • the lysed biomass may be dried by a process selected from the group consisting of spray drying, ribbon drying, tray drying, freeze drying, drum drying, vacuum ribbon drying, refractance window drying and vacuum drum drying.
  • the grown biomass may be dewatered to a concentration between 50 to 350 grams per liter (g/L).
  • the process does not include dewatering the grown biomass.
  • the method for producing a Euglena lysate may comprise growing a biomass from genus Euglena organisms, lysing the biomass, and drying the lysed biomass to form a Euglena lysate.
  • a method for producing a purified beta- 1 ,3-glucan comprises growing a biomass from genus Euglena organisms, and in a non-limiting example, dewatering the grown biomass.
  • the method further comprises lysing the biomass to form a lysed biomass, washing and dewatering the lysed biomass to produce a beta-l,3-glucan, and drying the beta-l,3-glucan to produce the purified beta-l,3-glucan.
  • the method may comprise washing and dewatering the lysed biomass a plurality of times.
  • the dewatering may comprise centrifuging or gravity decanting the biomass.
  • An example centrifuging is selected from the group consisting of decanter, stacked-disk, conical plate, pusher, and peeler centrifuging.
  • the lysing may be selected from the group consisting of mechanical, pH and temperature driven, surfactant, and enzymatic lysing.
  • the mechanical lysing may comprise homogenizing or bead milling the biomass, for example, homogenizing the biomass at a pressure greater than 500 barg at a pressure range of 500 to 1,900 barg, and in another example, at a pressure range of 750 to 1,000 barg.
  • the biomass may be lysed at a pH greater than 7.0 and at a temperature greater than 5 degrees centigrade. It is also possible to treat the biomass with a base and lyse the biomass at a pH greater than 7.0 and at a temperature greater than 45 degrees centigrade.
  • the biomass may be treated with a base and lysed at a pH between 7.0 to 12.5 and at a temperature between 45 to 100 degrees centigrade.
  • the biomass may be formed as a slurry having a concentration between 3 to 350 grams per liter (g/L), and more preferably, 50 to 175 g/L.
  • the lysing may comprise treating the biomass with a surfactant derived from fatty acids and comprising at least one of coconut oil, palm oil, palm kernel oil, and pilu oil.
  • the lysing may comprise treating the biomass with an acyl-amino surfactant derived from fatty acids and comprising at least one of coconut oil, palm oil, palm kernel oil, and pilu oil.
  • the lysing or treatment to make post lysis cellular fragments more amenable to washing may comprise treating the biomass with one or more of lysozyme, protease, lipase, or a combination.
  • the lysed biomass may be washed by treating the lysed biomass with one or more of water, acids, bases, ethanol, or a combination.
  • the drying may be selected from the group consisting of spray drying, ribbon drying, tray drying, freeze drying, drum drying, vacuum ribbon drying, refractance window drying and vacuum drum drying.
  • the grown biomass may or may not have to be dewatered before lysing.
  • the method for producing a purified beta-l,3-glucan may comprise growing a biomass from genus Euglena organisms, lysing the biomass to form a lysed biomass, washing and dewatering the lysed biomass to produce a beta-1,3-glucan, and drying the beta-l,3-glucan to produce the purified beta-I,3-glucan.
  • FIG. 1 is a high-level flowchart showing a preferred beta-glucan production process using a repeat fed batch fermentation in accordance with a non-limiting example.
  • FIG. 2 is another high-level flowchart showing a beta-glucan production process using continuous fermentation in accordance with a non-limiting example.
  • FIG. 3 is a high-level flowchart showing an example of downstream processing for making purified beta-glucan in accordance with a non-limiting example.
  • FIG. 4 is a high-level flowchart showing an example of downstream processing for making beta-glucan lysate in accordance with a non-limiting example.
  • FIG. 5 is a high-level flowchart showing an example of downstream processing for making whole cell Euglena gracilis in accordance with a non-limiting example.
  • FIG. 6 is a high-level flowchart of a beta-glucan production process using a combination of autotrophic, mixotrophic and heterotrophic in accordance with a non-limiting example.
  • FIG. 7 is an example of a capsule containing the composition formed from an example Euglena gracilis processing of FIG. 1 in accordance with a non-limiting example.
  • Beta-glucan from Euglena gracilis is also known by those skilled in the art as: beta-l,3-glucan, beta-l,3-D-glucan, paramylon, algae beta-glucan or Euglena beta-glucan.
  • Beta-glucan is a glucose polymer and the glucose linkages in the beta-glucan produced by Euglena gracilis are primarily 1,3 (>99%).
  • Other sources of beta-glucan have different ratios of 1,3, 1,4, 1,6, 2,3 and 3,6 linkages, and include branching and different polymer lengths, for example, beta-glucan produced from yeast as compared to beta-glucan produced from Euglena gracilis. These structural differences from other beta-glucan sources are believed to elicit different responses in in vivo animal trials. Alterations to the native beta-l,3-glucan structure with non-limiting functional group substitutions such as acylations, sulfonations, nitrations, phosphorylations or
  • carboxymethylations may beneficially alter the physicochemical properties of the glucan depending on use, for example, to improve solubility, product localization or binding site affinities.
  • FIG. 1 there is illustrated generally at 20 a sequence of processing steps that may be used for producing beta-glucan in accordance with a non-limiting example.
  • the process uses what is referred to as a repeat-fed batch fermentation and produces a composition as purified beta-glucan, a Euglena gracilis lysate or a dried Euglena biomass.
  • the process starts (Block 21) with a starter seed train (Block 22) and growing a culture heterotrophically in a Fernbach flask, for example, a standard sized flask known to those skilled in the art (Block 24).
  • a subculture portion is fed back while the other portions are passed into a seed vessel or tank (Block 26) and then to the fermentation tank.
  • fermentation continues in a repeat-fed batch fermentation process (Block 28) as explained in greater detail below using the sterilized feed (Block 30).
  • the fermentation process controls the temperature from 23-32°C, has a pH between 3-5, and a dissolved oxygen content between 10-40% with or without agitation provided by stirring and delivery of air or oxygen.
  • Nutritive sources may include glucose and other sugar or short chain fatty acids as the carbon source, amino acids or ammonia and salts therefrom for nitrogen, and trace metal components and vitamins.
  • At least one of existing and new fermentation growth components may be added to the fermentation batch during fermentation and at least a portion of the fermentation batch may be harvested to produce a biomass.
  • centrifuge technologies may be used for dewatering instead of a decanter centrifuge, such as a stacked-disk, conical plate, pusher, or peeler centrifuge. They are designed for large scale processing. Gravity decanting and other centrifuge techniques may be used to dewater the biomass in addition to other concentrating techniques such as filtration.
  • the biomass is lysed (Block 40) in a first pass only. It is also washed (Block 42) such as during the centrifugation, and after lysing and washing, it is spray dried (Block 44) as an example and packaged (Block 46) as a purified beta- glucan resulting from the wash.
  • the washing process is described below and can vary depending on the cell lysis technique used. To lyse the cells, various mechanical disrupting equipment, chemicals or other specialized lysing operations could be used.
  • the lysate or whole cell material composition may include the fermented material as including those components outside the algae cell that were in the fermentor and included in the composition as formed.
  • the composition may include some media and vitamins, even though many components may have been consumed during the fermentation process.
  • This may include a composition comprising a metal and a beta glucan, in which the metal may be zinc.
  • the composition may include the biomass lysate with proteins and amino acids, lipids, minerals such as the zinc, metabolites, vitamins, and beta- glucan. This combination of cellular fragments and other components may impart further advantageous properties to the final product. Those components outside the biomass that were in the fermentor may become part of the lysate product and composition for advantageous and useful benefits in various and possible dietary, medical, and cosmetic uses.
  • the starter seed train (Block 22) is now explained with the understanding that a first step in starting a heterotrophic culture is to prepare the media.
  • the seed train may be initiated from a slant, a plate, a frozen culture or other culture storage mechanism. Multiple passages in flasks starting from SO milliliters up to three liters or more may be used to prepare the culture for the seed vessel(s) and the starter seed train.
  • seed fermentation may occur.
  • seed vessel with culture passaged into a progressively larger seed vessel, prior to using the largest production fermentation equipment.
  • the purpose of the seed vessel(s) is the same as the seed train: to maximize biomass accumulation.
  • the seed vessel process is typically a batch fermentation process, but includes in one example a sterile feed for some or all media components. It may require aeration and some mixing to prevent biomass settling.
  • the final fermentation tank is usually the largest vessel and may be a limiting step in the overall facility output.
  • the purpose of the production fermentation vessel is to generate the molecule(s) of value.
  • the media used at this stage may include different components and additional changes and alterations to the media may be developed. As compared to the seed train and the overall seed fermentation, this stage of the process will not only accumulate additional biomass, but also will optimize paramylon production.
  • additional media may be added either continuously or at a discrete time in the fermentation batch.
  • the feed materials may be a whole media recipe, selected components or new components that are not included in the starting batch media. There can be multiple feeds which can start, stop, and have variable dosing rates at any time during the fermentation.
  • An additional process to the fed-batch fermentation could be aeration, mixing, temperature control and acid/base components for pH control or any combination of the listed.
  • the Repeat-Batch (Repeat-draw) process is a batch fermentation. However, at the end of a batch, a portion of the fermentation may be harvested as compared to a standard batch fermentation where the entire fermentor is harvested. New sterilized media may be added to the residual culture in the fermentor. Repeat batch can allow for higher inoculum amounts than can be delivered by a seed vessel. Additionally the tank turnaround time (downtime) and/or unproductive time may be reduced. A seed vessel is usually necessary to start the repeat-batch series, but may not be required for every batch, which lowers the seed train workload. An additional process to the repeat-batch fermentation could be aeration, mixing, temperature control and acid/base components for pH control or any combination of the listed.
  • the continuous fermentation process in FIG. 2 is similar to the Repeat-Fed Batch Fermentation except there is a continuous fermentation (Block 28a) instead of the Repeat-Fed Batch Fermentation (Block 28 in FIG. 1). Also, when continuous fermentation is used, there is no harvesting of the 5 to 95% of the batch (Block 32 in FIG. 1) and instead mere is a harvest storage to collect the continuous discharge from the fermentor (Block 32a).
  • a preferred technique would be to mechanically dewater through a decanter centrifuge followed by spray drying. Different centrifuge technologies may be used, such as a stacked-disk, conical plate, pusher, or peeler centrifuge.
  • a spray dry step could produce a flowable powder that can be heated to reduce the microbial bioburden. Additionally, the biomass slurry can be heated prior to spray drying to reduce microbial bioburden in the final material.
  • the biomass can also be ribbon dried, tray dried, freeze dried, drum dried, vacuum ribbon dried, refractance window dried, vacuum drum dried, or dried by other techniques known to those skilled in the art.
  • the whole lysate of the Euglena biomass is believed to be advantageous for a composition since it may have enhanced bioavailability and other functional benefits.
  • Dried lysate is the dried form of the preferred Euglena gracilis biomass in which the cell membrane, or more specifically the pellicle, has been lysed or disrupted. It should be understood that the lysate may be derived from any species of the genus Euglena. Lysis can occur through mechanical or chemical routes. In a non-limiting example, mechanical cell lysis can occur through
  • An alternative process at an industrial scale would be to mechanically lyse using a bead mill.
  • a non-limiting example of chemical lysis would be lysis from sodium hydroxide (NaOH) or other strong bases such as potassium hydroxide (KOH).
  • NaOH sodium hydroxide
  • KOH potassium hydroxide
  • a slurry of biomass at a concentration between 3 to 350 grams per liter (g/L), and more preferably, 50 to 175 g/L may be treated with NaOH at a concentration between about 0.05 to about 2 wt % or to a pH greater than 7.0 at a temperature greater than 5°C.
  • An example temperature range may be 50 to 70°C. This combination of temperature and base dosing disrupts the cells without requiring mechanical force. There may be greater bioavailability for the beta-glucan and other metabolites in a lysed form than in a whole- cell form.
  • the resulting dried lysate material may have an average particle size between 2-500 micrometers. More specifically, the average particle size may be 5-125 micrometers.
  • a preferred technique to produce dried biomass lysate is to mechanically disrupt a broth at a concentration between 3 to 350 g/L biomass, and more preferably, 50 to 175 g/L biomass.
  • a homogenizer is used at a pressure greater than 500 barg, which has been tested and shown to be effective in homogenization and generating freed beta-glucan granules.
  • An example range of operating a homogenizer may be about 500 to 1,900 barg and more optimally, 750 to 1,000 barg without requiring additional chemicals or additives to the process to lyse the biomass.
  • a bead mill could be used to mechanically lyse the biomass instead of a homogenizer.
  • the resulting lysate material is not washed or separated and it is dried through a spray drying process to preserve all present solids and non-volatile, soluble components.
  • the lysate material can also be ribbon dried, tray dried, freeze dried, drum dried, vacuum ribbon dried, refractance window dried, or vacuum drum dried as alternatives to spray drying. Other drying techniques known to those skilled in the art may be used. This process creates a material with beta-glucan freed from the biomass in addition to value added cellularly produced materials or cellular components with health benefits. There are also different techniques and options for producing purified paramylon therefrom. I. Mechanical Disruption
  • a preferred technique to produce dried purified beta-glucan is to mechanically disrupt a broth at a concentration between 3 to 350 g/L biomass, or more preferably, SO to 175 g/L biomass.
  • a homogenizcr can be used at a pressure greater than 500 barg, which has been tested and shown to be effective in homogenization and generating freed beta-glucan granules.
  • An example range of operating a homogenizcr may be about 500 to 1,900 barg and more optimally, 750 to 1,000 barg without requiring additional chemicals or additives to the process to lyse the biomass.
  • a bead mill could be used to mechanically lyse the biomass instead of a homogenizer.
  • the lysed material may be washed with water to remove cellular components. Additional washing may be performed using a base, acid, water or a combination therein.
  • a base for example, sodium hydroxide (NaOH) may be added to the lysed slurry at a 0.05 to 2.0 wt% concentration or to a pH greater than 7.0. It is possible to use other bases such as potassium hydroxide (KOH) and ammonium hydroxide (NH 4 OH) as non-limiting examples.
  • KOH potassium hydroxide
  • NH 4 OH ammonium hydroxide
  • Additional washes with water or 0.05 to 2.0 wt % caustic (NaOH) solutions can be completed. An acid wash is possible.
  • sulfuric acid may be added between 0.05 to 1.0 wt % or to a solution pH between 2.0 to 10.0 and preferably 3.0 to 5.0.
  • a final water wash may be made subsequent to the acid wash.
  • Other possible acids may include hydrochloric acid (HC1), phosphoric acid (H 3 PO 4 ), and citric acid (C 6 H 8 O 7 ) as non-limiting examples. Washing can also be accomplished by using ethanol and with any combination of the treatments above.
  • the beta- glucan slurry or cake should be dewatered between each washing step. Dewatering can occur with centrifugation or decanting after gravity settling. The resulting washed beta-glucan slurry or cake can be spray dried.
  • the material can be dried by a ribbon dryer, vacuum ribbon dryer, drum dryer, tray dryer, freeze dryer, refractance window dryer, vacuum dryer, or dried by other techniques known to those skilled in the art
  • a second technique to produce purified beta-glucan involves the treatment of a broth at a concentration between 3 to 350 g/L biomass, and more preferably, 50 to 175 g/L biomass with a surfactant such as sodium dodecyl sulfate (SDS) in concentrations of 0.2 to 2.0 wt %.
  • SDS sodium dodecyl sulfate
  • This solution is heated to between about 50°C to about 120°C with a temperature target of about 100°C for at least 30 minutes. This heated step in the presence of SDS disrupts the cell membrane and frees the intracellular paramylon crystal granules.
  • the slurry may be allowed to gravity decant for about 4 to 24 hours, while the crystal granules settle to the bottom of a reactor/decanter tank. The concentrated bottoms are pumped away for additional processing and the remaining liquid is sent to waste.
  • the material can be centrifuged to remove the bulk liquid in lieu of a gravity decant.
  • Different centrifuge technologies may be used, such as a stacked disk, conical plate, pusher, or peeler centrifuge.
  • a food-grade siloxane-based antifoam, such as Tramfloc 1174® or Xiameter 1S27®, added in greater than 20 ppm, more specifically 200 to 400 ppm may be used to reduce foaming caused by SDS.
  • the anti-foam can be added before or after the SDS/heat treatment if it is used.
  • the resulting material may be washed with water.
  • the resulting crystal slurry or cake can be spray dried.
  • the material can be dried by a ribbon dryer, vacuum ribbon dryer, drum dryer, tray dryer, freeze dryer, refractance window dryer, vacuum dryer, or dried by other techniques known to those skilled in the art.
  • a third technique to generate purified beta-glucan involves the treatment of a broth at a concentration between 3 to 350 g/L biomass, and more preferably, 50 to 175 g/L biomass with a surfactant produced from natural oils such as sodium cocoyl glycinate or sodium N-cocoyl-L-alaninate (Amilite® ACS12) derived from the fatty acids in coconut oil in an amount of about 0.2 to about 5.0 wt %.
  • This solution is heated to between about 50°C to about 120°C with a current target of about 100°C for at least 30 minutes.
  • This heat step in the presence of sodium N-cocoyl-L-alaninate or sodium cocoyl glycinate disrupts the cell membrane and frees the intra-cellular paramylon crystal granules.
  • the time, temperature, and concentration parameters may be refined depending on the exact surfactant used.
  • the slurry is allowed to gravity decant for about 4 to 24 hours while the crystal granules settle to the bottom of a reactor/decanter tank.
  • the concentrated bottoms may be pumped for additional processing while the remaining liquid is sent to waste.
  • the material may be processed through a centrifuge to remove the bulk liquid in lieu of a gravity decant.
  • Different centrifuge technologies may be used, such as stacked-disk, conical plate, pusher, or peeler centrifuging.
  • An anti-foam may be added.
  • An example anti-foam material is a food-grade siloxane-based antifoam, for example, Tramfloc 1174® or Xiameter 1527®.
  • the anti-foam may be used to reduce foaming caused by the surfactant.
  • the anti-foam may be added before or after the surfactant/heat treatment if it is applied.
  • An example dosing range includes an amount greater than 20 ppm, more specifically 200 to 400 ppm.
  • the resulting material may be washed with water.
  • the resulting crystal slurry or cake can be spray dried.
  • the material can be dried by a ribbon dryer, vacuum ribbon dryer, drum dryer, tray dryer, freeze dryer, refractance window dryer, vacuum dryer, or dried by other techniques known to those skilled in the art.
  • Amino acid-based surfactants derived from coconut oil fatty acids are anionic and demonstrate a lower potential for outer layer skin damage, while also exhibiting equal or greater cleansing ability. These attributes are described in the article by Regan et al. entitled, “A Novel Glycinate-Based Body Wash,” Journal of Clinical and Aesthetic Dermatology, June 2013; Vol. 6, No. 6, pp. 23-30, the disclosure which is hereby incorporated by reference.
  • Sodium cocoyl glycinate is composed of N-terminally linked glycine with a spectrum of fatty acids in natural coconut oil containing carbon lengths and percentages of 10, 12, 16, 18: 1 and 18:2 and 6, 47, 18, 9, 6 and 2 respectively such as described in the report from National Industrial Chemicals Notification and Assessment Scheme, Sodium Cocoyl Glycinate, EX/130 (LTD/1306), August 2010, the disclosure which is hereby incorporated by reference. Both sodium N-cocoyl-glycinate and sodium N-cocoyl-L-alaninate are examples of coconut oil derived surfactants.
  • surfactants derived from palm oil, palm kernel oil, and pilu oil which are similar to coconut oil based on the ratios and distribution of the fatty acids sized from C8 to CI 8.
  • coconut oil contains a large amount of lauric acid (CI 2) but also a significant amount of caprylic (C8), decanoic (CIO), myristic (C14), palmitic (CI 6), and oleic acids (CI 8).
  • Palm oil, palm kernel oil, and pilu oil have similar fatty acid profiles as coconut oil which means surfactants derived from these oils could be equally effective than surfactants derived from the fatty acids in coconut oil. These may also be suitable alternatives to SDS. The ranges and content of these fatty acids as naturally derived surfactants may vary.
  • a fourth technique to produce purified beta-glucan is to chemically disrupt the biomass using a base.
  • a non-limiting example would be lysis from sodium hydroxide (NaOH) or other bases such as potassium hydroxide (KOH).
  • NaOH sodium hydroxide
  • KOH potassium hydroxide
  • to disrupt the cell a slurry of biomass at a concentration between 3 to 350 grams per liter (g/L), and more preferably, 50 to 175 g/L may be treated with NaOH at a concentration between about 0.05 to about 2 wt % or to a pH greater than 7.0 at a temperature greater than 5°C.
  • a non-limiting example temperature range may be 45 to 70°C and pH range may be 9.0 to 12.5. This combination of temperature and base dosing disrupts the cells without requiring mechanical force.
  • a first treatment with the base should lyse the cells. If too little base is applied or the temperature is too low, the cells may not be disrupted, and if too much base is applied and/or the temperature is too high, most components and the beta-glucan may go into solution. Washing with water may be performed. Additional washing may be performed using a base, an acid, or water in sequence or any combination, such as acid, a base, and then water.
  • Additional washes with water or 0.05 to 1.0 wt % sodium hydroxide (NaOH) solutions or to a pH greater than 7.0 can be completed.
  • Potassium hydroxide (KOH) will also work.
  • Other possible bases include ammonium hydroxide (NH4OH) as a non-limiting example.
  • An acid wash may be completed. For example, sulfuric acid may be added between 0.05 to 1.0 wt % or to a solution pH between 2.0 to 10.0 and preferably 3.0 to 5.0 can be completed and a final wash with water may be made subsequent to the acid wash.
  • washing can also be accomplished by using ethanol and with any combination of the treatments above.
  • the beta-glucan slurry or cake should be dewatered between each washing step. Dewatering can occur with centrifugation or gravity decanting. Different centrifuge technologies may be used, such as a stacked disk, conical plate, pusher, or peeler centrifuge.
  • the resulting washed beta-glucan slurry or cake can be spray dried. Alternatively, the material can be dried by a ribbon dryer, vacuum ribbon dryer, drum dryer, tray dryer, freeze dryer, refractance window dryer, vacuum dryer, or dried by other techniques known to those skilled in the art
  • a fifth technique to produce purified beta-glucan focuses on enzymatic treatment
  • Cell lysis may occur through mechanical disruption or other treatments as described above and the biomass can be at a concentration between 3 to 350 g/L, and more preferably, 50 to 175 g/L. Cell lysis prior to treatment may also not be required.
  • the pH and temperature of the slurry can be adjusted with an acid or base and energy to meet the conditions required for optimal enzymatic treatment
  • a non-specific protease can be used to degrade proteins from the cells.
  • a non-limiting example could be Alcalase® 2.4L FG from Novozymes. The resulting
  • enzymatically treated slurry can be washed with an acid, base, ethanol, or water, or any combination therein, in order to remove the enzymatically treated components and then dewatered.
  • Dewatering can occur with centrifugation or gravity decanting. Different centrifuge technologies may be used, such as a stacked disk, conical plate, pusher, or peeler centrifuge.
  • the resulting beta-glucan slurry or cake can be spray dried.
  • die material can be dried by a ribbon dryer, vacuum ribbon dryer, drum dryer, tray dryer, freeze dryer, refractance window dryer, vacuum dryer, or dried by other techniques known to those skilled in the art.
  • Other enzymes such as a lipase may be used in addition to the protease.
  • Another example is a lysozyme used alone or in combination.
  • an enzyme deactivation step may be required. The amount of post enzyme treatment washing may be determined during processing but could follow the processes outlined above.
  • FIO. 3 is a flowchart showing downstream processes for making the purified beta- glucan. Reference numerals corresponding to those shown in FIG. 1 are used with reference to the general description of flow components as in FIG. 1.
  • the fermentation process creates the Euglena biomass (Block 28) that is dewatered to concentrate the biomass (Block 34).
  • Dewatering could include processing by the preferred decanter centrifuge or the other centrifuge techniques including stacked-disc, conical plate, pusher and peeler centrifuging. It is also possible to use gravity decantation.
  • the cell lysis process disrupts the cellular pellicle and can be accomplished using a mechanical lysis (Block 40a), including the preferred homogenizer or bead mill as described above.
  • a pH mediated lysis (Block 40b) may include sodium hydroxide (NaOH) as a preferred base at approximately 50 to 70°C with other possibilities and further processing including OH at greater than S°C, NH OH at greater than 5°C and other bases at greater than 5°C.
  • Another example may include enzymatic lysis (Block 40c) and may include protease, lipase, lysozyme or a combination of those processes.
  • the protease is an enzyme that catalyzes proteolysis with the use of water to hydrolyze protein and peptide bonds while the lipase enzyme catalyzes the hydrolysis of lipids.
  • a lysozyme enzyme typically operates as a glycoside hydrolase.
  • Another example of the cell lysis process includes using a surfactant lysis (Block
  • the washing step cleans out the non-beta-glucan components and may include a purification by washing (Block 42a). This may include adding a base and acid with water and any combinations for the preferred process, including sodium hydroxide ( aOH) followed by sulfuric acid (H2SO4), and water.
  • SDS sodium dodecyl sulfate
  • H2SO4 sulfuric acid
  • the purification may occur by enzymatic treatment (Block 42b) that includes the protease, lipase, or combinations with the potential water wash at the treatment. Purification may also occur by washing (Block 42c) with water and a siloxanc-based anti-foam or a combination.
  • the final step of drying (Block 44) may include a preferred spray drying or tray drying, vacuum ribbon drying, refractance window drying, freeze drying, ribbon drying, drum drying, or vacuum drying as alternatives, as well as other techniques known to those skilled in the art.
  • FIG. 4 is a flowchart showing downstream processes for making the beta-glucan lysate. Reference numerals corresponding to those shown in FIG. 1 are used with reference to the general description of flow components as in FIG. 1.
  • the fermentation process creates the Euglena biomass (Block 28) that is dewatered to concentrate the biomass (Block 36).
  • Dewatering could include processing by the preferred decanter centrifuge or the other centrifuge techniques including stacked-disk, conical plate, pusher, and peeler centrifuging. It is also possible to use gravity decantation.
  • the cell lysis process disrupts the cellular pellicle (Block 48) and can be accomplished using a mechanical lysis (Block 48a), including the preferred homogenizer or bead mill as described above.
  • a pH mediated lysis (Block 48b) may include sodium hydroxide (NaOH) as a preferred base at approximately 50 to 70°C with other possibilities and further processing, including KOH at greater than 5°C, NH4OH at greater than 5°C, and other bases at greater than S°C.
  • Another example may include enzymatic lysis (Block 48c) and may include protease, lipase, lysozyme, or a combination of these processes. Drying occurs (Block SO) with a preferred spray drying and may include tray drying, ribbon vacuum drying, refractance window drying, and freeze drying.
  • FIG. 5 is a flowchart showing downstream processes for making the whole cell Euglena gracilis. Again, reference numerals corresponding to those shown in FIG. 1 are used with reference to the general description of flow components as in FIG. 1.
  • the fermentation process creates the Euglena biomass (Block 38) that is dewatered to concentrate the biomass (Block 38). Again, the decanter centrifuge is the preferred operation and other processes as described relative to FIG. 4 may also be used. Drying occurs (Block 54) with spray drying as preferred and with other drying techniques that may be applicable as described with reference to FIG. 4.
  • FIG. 6 Another example of a beta-ghican production process is shown in FIG. 6 at 100 and shows a method for producing beta-l,3-glucan using a combination of autotrophic, mixotrophic, and heterotrophic growth techniques.
  • the beta- 1,3- glucan is produced by culturing Euglena gracilis.
  • the starting culture for the process may be initiated from starter slants or other stored culture source. It is then grown autotrophically. This is followed by converting the batch to mixotrophic growth by adding glucose.
  • the mixotrophic material is then used to inoculate a heterotrophically operated Euglena gracilis fermentation.
  • the process (Block 100) starts (Block 101) and a starter slant is prepared (Block 102).
  • the Euglena gracilis seed culture is grown autotrophically in a seed carboy (Block 106) with the sub-culture portion fed back to new carboys.
  • the Euglena gracilis seed culture is grown autotrophically, it is fed sterilized glucose (Block 118), which converts it into a mixotrophic seed carboy (Block 120).
  • the autotrophically grown Euglena gracilis seed culture is now grown mixotrophically for about 7 to about 30 days and then used to inoculate a fermentation tank where heterotrophic fermentation occurs for about 4 to about 7 days (Block 122). This process of heterotrophic fermentation occurs for about 4 to about 7 days to produce beta-glucan rich Euglena gracilis.
  • a Euglena gracilis biomass is removed and dewatered by a centrifugation (Block 128) followed by drying (Block 130) in an oven.
  • the biomass cake is dried at about 80 °C to 120 °C.
  • the material may be ground and milled (Block 132) followed by screening and vacuum packing (Block 134) followed by pasteurization (Block 136).
  • the pasteurization temperature range may vary and in one example may be about 160 °C and run for no less than 2 hours.
  • the product may be packed for human or animal use (Block 138). Also, the centrifugate as water (Block 140) is processed as waste (Block 142).
  • a lysate composition delivery system 200 includes a capsule 214 containing the final product as the lysate 216 produced from the process such as described in FIG. 1.
  • the capsule 200 may be formed from conventional upper and lower capsule sections 214a and 214b.
  • other delivery mechanisms such as tablets, powders, lotions, gels, liquid solutions and liquid suspensions are also possible.
  • the capsule material 216 contains not only a linear, unbranched beta- glucan 220, but also other material from the fermentor that creates an enhanced composition. These components may include lipids 222, proteins and amino acids 224, metabolites 226, minerals such as zinc 228 and vitamins 230, and other value added, cellularly produced components and cellular materials.
  • This composition therefore includes in one example a Euglena lysate additionally including cellular components and residual media remaining from the fermentation batch that produced the Euglena lysate.
  • the composition also includes various additive metal components such as zinc. An example range for metal components, including zinc, are 0.1 to 10 wt%.
  • the composition is delivered in a single dosage capsule.
  • Some of the beta-glucan components may include one or more beta-glucan polymer chains and vary in molecular weight from as low as 1.2 kDa to as high as S80 kDa and have a polymer length ranging from as low as 7 to as high as 3,400 glucose monomers as one or more polymer chains.
  • the beta-glucan polymers can exist individually or in higher order entities such as triple helices and other intermolecularly bonded structures dependent upon fermentation or processing conditions.
  • An example mean particle size range could be 2.0 to 500 micrometers (microns) for the lysate produced by the processes as described. More specifically, the average particle size may be 5- 125 micrometers.
  • lysate composition examples include carotenoids such as alpha- and beta-carotene, astaxanthin, lutein, and zeaxanthin.
  • Amino acids may be included such as alanine, arginine, aspartic acid, cysteine, cystine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine.
  • lipids, vitamins and minerals include arachidonic acid, biotin, calcium, copper, docosahexaenoic acid, eicosapentaenoic acid, fats, folic acid, iron, linoleic acid, linolenic acid, magnesium, manganese, niacin, oleic acid, palmitoleic acid, pantothenic acid, phosphorus, potassium, protein, sodium, vitamin Bl , B2, B6, B12, C, D, E, l, zinc or salts therefrom, as well as leftover components from the Euglena algae, including other cellular components not listed above and added media obtained from fermentation.
  • the ranges of supplementation may vary.
  • the composition can range from 50 to 6,000 mg per kilogram of food or from about SO mg to 2,000 mg as a capsule dosage. These amounts can vary depending on the end uses and may vary even more when used for other uses. In certain examples, this may include animal uses.
  • the desired response from glucan supplementation can vary.
  • soluble and particulate beta-glucans have elicited biological effects beyond immune modulation.
  • antimicrobial, antiviral, anti tumoral, antifibrotic, antidiabetic and anti-inflammatory responses as well as evoking microbiome sustenance, in the form of a prebiotic, hepatoprotective, hypoglycemic, cholesterol lowering, wound healing, bone marrow trauma and radiation and rhinitis alleviating effects.
  • the bioactivities mentioned are triggered by glucans and may then have potential applications in treatments of viral and bacterial infection, cancer, cardiovascular disease, liver disease, blood disorders, diabetes, hypoglycemia, trauma, skin aging, aberrant myelopoiesis, arthritis, microbiome deficiencies, ulcer disease and radiation exposure. Additionally outside the scope of human health, beta glucan has potential applications in animal husbandry. Beta glucans can potentially improve growth performance by allowing the livestock to grow at optimal rates through immune modulation to combat growth rate deterrents such as disease and environmental challenges common to the trade.
  • beta glucans could specifically provide preventative measures in contracting significant animal diseases in non-limiting examples such as Porcine Respiratory and Reproductive Syndrome (PRRS), Porcine Epidemic Diarrhea virus (PEDv), Newcastle disease and avian influenza. Additionally beta glucans can have absorptive effects for mycotoxins produced by fungal infection. This indicates potential for preventing mycotoxin production by having fungicidal activity initially or clearing mycotoxin accumulations in animals from mycotoxin contaminated feed ingestion.
  • PRRS Porcine Respiratory and Reproductive Syndrome
  • PEDv Porcine Epidemic Diarrhea virus
  • Newcastle disease avian influenza
  • avian influenza avian influenza
  • beta glucan derived products may be added with other natural foods and remedies including echinacea, aloe, golden seal, ginseng, garlic, bell peppers, ginger, tumeric, gingko biloba, cat's claw, ganoderma or astragalus. It may be mixed further with vitamin C and possibly bumic and fulvic acids. It is also possible to mix glucan with resveratrol or other polyphenols and work for treating heart disease and possibly cancer.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Materials Engineering (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition qui comprend un lysat et des composants cellulaires d'Euglena et un milieu cellulaire subsistant après un procédé de fermentation qui produit une biomasse d'Euglena et le lysat d'Euglena. Les composants cellulaires peuvent comprendre une ou plusieurs chaînes polymères de bêta-glucane ayant un poids moléculaire de 1,2 à 580 kilodaltons (kDa). L'invention concerne un procédé de production d'un lysat d'Euglena qui comprend la croissance d'une biomasse d'organismes du genre Euglena, la lyse de la biomasse et le séchage de la biomasse lysée pour former un lysat d'Euglena. L'invention concerne un procédé de production d'un bêta-1,3-glucane purifié qui comprend la croissance de la biomasse, sa lyse, son lavage et sa déshydratation et son séchage.
EP17810911.2A 2016-06-09 2017-06-07 Composition de lysat d'euglena et procédé de production de la composition d et d'un bêta-1,3-glycane purifié Withdrawn EP3469089A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15/177,376 US20170354698A1 (en) 2016-06-09 2016-06-09 Method of producing a euglena lysate
US15/177,368 US20170356020A1 (en) 2016-06-09 2016-06-09 Method of forming a purified beta-1,3,-glucan
US15/177,383 US9901606B2 (en) 2016-06-09 2016-06-09 Euglena lysate composition
PCT/US2017/036270 WO2017214224A1 (fr) 2016-06-09 2017-06-07 Composition de lysat d'euglena et procédé de production de la composition d et d'un bêta-1,3-glycane purifié

Publications (2)

Publication Number Publication Date
EP3469089A1 true EP3469089A1 (fr) 2019-04-17
EP3469089A4 EP3469089A4 (fr) 2019-05-08

Family

ID=60578946

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17810911.2A Withdrawn EP3469089A4 (fr) 2016-06-09 2017-06-07 Composition de lysat d'euglena et procédé de production de la composition d et d'un bêta-1,3-glycane purifié

Country Status (6)

Country Link
EP (1) EP3469089A4 (fr)
JP (1) JP2019523654A (fr)
KR (1) KR20190008422A (fr)
CN (1) CN109477125A (fr)
AU (1) AU2017277413B2 (fr)
WO (1) WO2017214224A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102083165B1 (ko) * 2019-09-18 2020-03-02 대상 주식회사 베타-1,3-글루칸 생산능을 갖는 신규의 유글레나 속 균주 및 이를 이용한 베타-1,3-글루칸을 함유하는 유글레나 균체의 제조방법
CN112481330B (zh) * 2020-12-18 2023-06-13 天津科技大学 一种藻源β-1,3-葡聚糖发酵生产方法
CN113968918A (zh) * 2021-11-04 2022-01-25 大连工业大学 一种绿色高效制备水溶性裸藻β-葡聚糖的方法及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0409488A3 (en) * 1989-07-17 1991-08-07 Takeda Chemical Industries, Ltd. Method for producing a heat-gelable beta-1,3-glucan
DE59901613D1 (de) * 1999-02-10 2002-07-11 Suwelack Skin & Health Care Ag Beta-1,3-Glucan aus Euglena enthaltendes gefriergetrocknetes Erzeugnis, seine Herstellung und Verwendung
FR2880802B1 (fr) * 2005-01-14 2008-12-19 Sederma Soc Par Actions Simpli Composition cosmetique ou dermopharmaceutique contenant un extrait d'euglene
JP2010233513A (ja) * 2009-03-31 2010-10-21 Sanyo Chem Ind Ltd 培地添加剤
WO2013126669A1 (fr) * 2012-02-22 2013-08-29 Algal Scientific Corporation Compositions alimentaires pour animaux et leurs procédés d'utilisation
BR112014027989A2 (pt) * 2012-05-07 2017-07-18 Algal Scient Corporation processo multi-etapas para produção de modulador imunológico
MX363063B (es) * 2013-03-14 2019-03-06 Algal Scient Corporation Modulacion de la funcion del sistema inmunitario de las plantas.
BR112015024308B8 (pt) * 2013-03-27 2023-05-02 Kobelco Eco Solutions Co Ltd Método para a produção de polissacarídeos e método para a produção de um composto orgânico

Also Published As

Publication number Publication date
EP3469089A4 (fr) 2019-05-08
WO2017214224A1 (fr) 2017-12-14
AU2017277413A1 (en) 2018-12-13
KR20190008422A (ko) 2019-01-23
JP2019523654A (ja) 2019-08-29
AU2017277413B2 (en) 2020-04-30
CN109477125A (zh) 2019-03-15

Similar Documents

Publication Publication Date Title
Amorim et al. Microalgae proteins: Production, separation, isolation, quantification, and application in food and feed
CN107287252B (zh) 一种ω-7脂肪酸合成物及培养黄丝藻生产该合成物的方法与应用
US9574217B2 (en) Multi-stage process for production of immune modulator
AU2017277413B2 (en) Euglena lysate composition and method for producing the composition and a purified beta-1,3-glucan
Lee et al. Separation and biosynthesis of value-added compounds from food-processing wastewater: Towards sustainable wastewater resource recovery
Tounsi et al. Microalgae as feedstock for bioactive polysaccharides
CN1642986A (zh) 来自生物量的细胞壁衍生物和其制品
US11279962B2 (en) Chitin and chitosan producing methods
Prybylski et al. Bioactive polysaccharides from microalgae
JP2020501547A (ja) バイオマス材料からの核酸及びそのフラグメントの除去
US9901606B2 (en) Euglena lysate composition
Acquah et al. Potential applications of microalgae-derived proteins and peptides in the food industry
WO2019160599A1 (fr) Composition issue d'euglène, notamment une composition d'aliment pour animaux
US20180168190A1 (en) Euglena derived animal feed composition
US20170356020A1 (en) Method of forming a purified beta-1,3,-glucan
US20170354698A1 (en) Method of producing a euglena lysate
Chavan et al. Ultrasound-assisted extraction of proteins and carbohydrates
JPWO2019130535A1 (ja) ラビリンチュラ類の培養方法
Bhagea et al. Microalgae as sources of green bioactives for health-enhancing food supplements and nutraceuticals: A review of literature
Doan et al. Protein Extraction from Spirulina Platensis with The Cellulase Enzyme Assistance
US20180200314A1 (en) Euglena derived composition having biomass and immune response inducing components
MX2010010162A (es) Nutriente enterico.
Bera et al. Strong antioxidant property of bacterial canthaxanthin obtained by raw coconut water supplementation as an additional nutrient source
KR20130015037A (ko) 미세녹조류를 이용한 항염증 및 항여드름효능을 가지는 추출물 및 그의 제조방법
US20180169161A1 (en) Euglena derived composition having immune response inducing components

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20190408

RIC1 Information provided on ipc code assigned before grant

Ipc: A23L 33/105 20160101ALI20190402BHEP

Ipc: C12P 1/00 20060101ALI20190402BHEP

Ipc: C12P 19/04 20060101AFI20190402BHEP

Ipc: C08B 37/00 20060101ALI20190402BHEP

Ipc: A23L 33/15 20160101ALI20190402BHEP

Ipc: A23L 33/175 20160101ALI20190402BHEP

Ipc: A23L 33/125 20160101ALI20190402BHEP

Ipc: A23L 33/12 20160101ALI20190402BHEP

Ipc: A23L 33/16 20160101ALI20190402BHEP

Ipc: A23L 33/10 20160101ALI20190402BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210112